creativebiolabs's blog

Recently, a paper titled "Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity" was published online in the international journal Cell Metabolism by scientists from Swansea University and other institutions. They found that canagliflozin may potentially be used to treat autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, because it can target T cells, which are an essential part of the immune system.

A research team from China has developed an mRNA-based T-cell-inducing antigen vaccine that strengthens the COVID-19 vaccine against SARS-CoV-2 variants.

Herd immunity through mass vaccination is an effective way to prevent infectious diseases. However, the common SARS-CoV-2 mutant strains have largely escaped the humoral immunity induced by the COVID-19 vaccine, which was developed on the basis of the S protein.

Nonsense mutations, which occur when a sense codon in a protein-coding sequence becomes a premature termination codon (PTC), are responsible for approximately 11% of human genetic diseases.

The translational process of mRNA to protein is carried out by tRNA, which recognizes the codon on mRNA by its own anticodon and transports the amino acid corresponding to the codon to the polypeptide chain in ribosome synthesis.

G protein-coupled receptors (GPCRs) play an important role in cellular signaling and serve as important therapeutic targets for a variety of diseases. Upon binding to extracellular agonists, GPCRs stimulate distinct signaling pathways by recruiting different G proteins (Gs, Gi, Gq, etc.,) to mediate a variety of physiological functions. Selective conjugation between GPCRs and specific G proteins is essential for the biological role of such receptors.

Most people today are immune to SARS-CoV-2, the coronavirus that causes COVID-19, thanks to widespread vaccination campaigns and unplanned infection. Although this widespread immunity hasn't stopped new infections from happening, it has slowed the devastating spread of illness and death that the initial COVID-19 epidemic caused. As the virus evolves and produces novel strains that can partially dodge vaccines and antibodies created by past infections, it is imperative that this degree of protection be maintained.

Scientists from MIT and the Broad Institute have leveraged an existing bacterial system to create a novel strategy for protein delivery that is effective in both human and animal cells. This technique may be used to target certain cell types for the delivery of a wide range of proteins, including those employed in gene editing. This approach shows promise as a reliable vehicle for the transport of therapeutic agents in the fields of gene therapy and cancer treatment.